Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
8.97
+0.29 (3.34%)
At close: Feb 18, 2026, 4:00 PM EST
9.14
+0.17 (1.90%)
After-hours: Feb 18, 2026, 7:24 PM EST
Fennec Pharmaceuticals Revenue
Fennec Pharmaceuticals had revenue of $12.46M in the quarter ending September 30, 2025, with 78.69% growth. This brings the company's revenue in the last twelve months to $38.79M, down -21.39% year-over-year. In the year 2024, Fennec Pharmaceuticals had annual revenue of $47.54M with 123.69% growth.
Revenue (ttm)
$38.79M
Revenue Growth
-21.39%
P/S Ratio
7.90
Revenue / Employee
$1,212,188
Employees
32
Market Cap
306.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 47.54M | 26.29M | 123.69% |
| Dec 31, 2023 | 21.25M | 19.72M | 1,284.50% |
| Dec 31, 2022 | 1.54M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 170.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 82.55M |
| XOMA Royalty | 47.11M |
| AC Immune | 5.48M |
| Armata Pharmaceuticals | 5.05M |
| Abeona Therapeutics | 400.00K |
| Avalo Therapeutics | 192.00K |
FENC News
- 7 weeks ago - Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) - GlobeNewsWire
- 2 months ago - Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026 - Seeking Alpha
- 2 months ago - Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors - GlobeNewsWire
- 2 months ago - Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss - GlobeNewsWire
- 3 months ago - Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Fennec Pharmaceuticals Announces Closing of Offering of Common Shares - GlobeNewsWire
- 3 months ago - Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada - GlobeNewsWire
- 3 months ago - Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares - GlobeNewsWire